What's Happening?
SonoMotion, a medical technology company based in San Mateo, California, has announced that its Break Wave lithotripsy device has met the primary efficacy and safety endpoints in a pivotal clinical trial. The device, which uses low-pressure focused ultrasound
to fragment kidney stones, is non-invasive and does not require anesthesia, allowing patients to resume normal activities immediately after the procedure. The trial results will be presented at the American Urological Association annual meeting. Additionally, SonoMotion has received FDA 510(k) clearance for a next-generation version of the device, which features a more compact design. The company plans to begin commercialization in the latter half of 2026.
Why It's Important?
The Break Wave device represents a significant advancement in the treatment of kidney stones, a condition affecting one in ten people in the U.S. and costing the healthcare system $10 billion annually. Traditional treatments often require invasive procedures and anesthesia, leading to longer recovery times and higher healthcare costs. By offering a non-invasive, anesthesia-free option, SonoMotion's technology could reduce the burden on patients and healthcare providers, potentially becoming a first-line treatment. The FDA clearance and successful trial outcomes position SonoMotion to address a large market need, potentially improving patient outcomes and reducing healthcare costs.
What's Next?
With FDA clearance secured, SonoMotion is poised to begin commercializing the Break Wave device in the second half of 2026. The company will likely focus on expanding its market presence and educating healthcare providers about the benefits of its non-invasive technology. The upcoming presentation at the American Urological Association meeting will provide a platform to showcase the device's capabilities to a wide audience of urology professionals. As the device enters the market, it may prompt other companies to develop similar non-invasive solutions, potentially transforming the standard of care for kidney stone treatment.
